Introduction
============

Levobetaxolol hydrochloride was introduced in the early 1980s as the first cardioselective β~1~-adrenergic antagonist for the treatment of elevated intraocular pressure (IOP) ([@b4-opth-1-93]).

Levobetaxolol is a single active isomer of betaxolol, a cardioselective β~1~-adrenergic receptor-blocking agent (betaxolol is a racemic mixture of D- and the active L-isomers).

Since racemic betaxolol and other β-adrenergic antagonists have been shown to reduce IOP by a reduction of aqueous production as demonstrated by tonography and aqueous fluorophotometry, it is assumed that levobetaxolol has a similar mechanism of action ([@b39-opth-1-93]). Betaxolol, by having a greater affinity for cardiac (β~1~) than pulmonary receptors (β~2~), has been demonstrated to offer a reduced potential for pulmonary side effects, particularly in patients with pulmonary diseases ([@b56-opth-1-93]).

Several clinical studies have demonstrated the IOP lowering effect of the drug, in patients affected with primary open-angle glaucoma (POAG) and ocular hypertension (OHT) ([@b38-opth-1-93]; [@b6-opth-1-93];[@b13-opth-1-93]).

β-blockers can act as a neuroprotectant by reducing sodium influx into cells, and can also protect insulted neurones by reducing influx of calcium. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium influx, which might confer a neuroprotective activity ([@b20-opth-1-93]).

Experimental and clinical studies have demonstrated the effects of levobetaxolol on ocular hemodynamics and visual fields, and the pharmacology differences between β-blockers currently used for the treatment of elevated IOP have become of more than academic interest since a number of studies have shown improvements to various extents (Drance 1998, [@b12-opth-1-93]; Turacli et al 1998; [@b18-opth-1-93],[@b19-opth-1-93]).

Unlike the initially manufactured 0.5% ophthalmic solution, levobetaxolol is suspended in a different delivery vehicle in levobetaxolol ophthalmic suspension, to increase the ocular tolerance and allow a similarity of effect with a 2-fold reduced concentration (0.25%). The cationic exchange resin in which levobetaxolol is suspended provides microscopic beads 5 microns in diameter, and residence time in the cul-de-sac is increased with the addition of a poly-acrylic polymer ([@b55-opth-1-93]; [@b59-opth-1-93]). It has been demonstrated that levobetaxolol ophthalmic suspension has similar efficacy in reducing the IOP in POAG and OHT patients when compared with betaxolol solution ([@b54-opth-1-93]).

The present paper provides a brief review of the literature on the pharmacologic and clinical investigations on levobetaxolol.

Levobetaxolol hydrochloride ophthalmic suspension
=================================================

In comparisons between non-cardioselective β-blockers in reactive airway subjects, levobetaxolol was demonstrated to have less effect on pulmonary function (FEV~1~ and forced vital capacity \[FVC\]) ([@b43-opth-1-93]), by having a greater affinity for cardiac than pulmonary receptors.

The cardiovascular effects of levobetaxolol were compared in double-masked, crossover studies with timolol maleate ophthalmic solution 0.5%. Levobetaxolol was shown during exercise to have significantly less effect on heart rate and systolic blood pressure than timolol maleate ([@b36-opth-1-93];[@b58-opth-1-93]).

Betaxolol, a racemic mixture of D and the active L-isomers, is commercially available in two forms: 0.5% ophthalmic solution, and the 0.25% ophthalmic suspension.

IOP reduction
=============

β-adrenergic receptors are present in the ciliary epithelium-process, choroid, retina, iris, and longitudinal and circular ciliary muscles, and at a lower percentage in the lens and cornea ([@b46-opth-1-93]). They are also found in the trabecular meshwork ([@b59-opth-1-93]). Aqueous humor production is mediated by the non-pigmented ciliary epithelial cells of the ciliary process ([@b34-opth-1-93]).

A rise in cAMP causes an increase in aqueous formation mediated by β-agonist activity ([@b33-opth-1-93];[@b49-opth-1-93];[@b44-opth-1-93]). Aqueous humor outflow is increased by adrenergic stimulation relaxing (cAMP stimulation) trabecular meshwork ([@b32-opth-1-93];[@b31-opth-1-93];[@b57-opth-1-93]).

Epinephrine and isoproterenol enhance aqueous humor outflow, reducing cell area and increasing intercellular space in trabecular meshwork and Schlemm's canal endothelial cells through a β-stimulation ([@b10-opth-1-93]).

In non-pigmented ciliary epithelial cells, levobetaxolol was more potent than dextrobetaxolol or racemic betaxolol at inhibiting isoproterenol-stimulated cAMP production ([@b30-opth-1-93];[@b10-opth-1-93]).

Experimental data on the inhibition of adenylyl cyclase activity in non-pigmented ciliary epithelial cells and trabecular meshwork cells demonstrate that β~2~-receptors predominate in ciliary body and trabecular meshwork ([@b29-opth-1-93];[@b9-opth-1-93];[@b53-opth-1-93];[@b14-opth-1-93];[@b10-opth-1-93]).

Levobetaxolol would therefore be expected to be more potent in decreasing aqueous humor production than dextrobetaxolol, which is supported by the fact that levobetaxolol is more potent in decreasing IOP than dextrobetaxolol. Levobetaxolol was 89-fold β~1~-selective relative to its potency at β~2~-receptors in functional assays using isolated animal tissues (guinea pig atria for β~1~-receptors, guinea pig tracheal rings for β~2~-receptors). In this study levobetaxolol demonstrated higher β~1~- and β~2~-receptor affinities and functional potencies, and a higher β~1~-selectivity than dextrobetaxolol. Levobunolol and (l)-timolol, while having high affinities and potencies at β~1~- and β~2~-receptors, exhibited insignificant β-receptor selectivity (2- and 3-fold β~1~-selective) ([@b46-opth-1-93]). Levobetaxolol exhibited a higher affinity at cloned human β~1~-(ki = 0.76 nM) than at β~2~-(ki = 32.6 nM) receptors, while dextrobetaxolol was much weaker at both receptors (43-fold β~1~-selectivity for levobetaxolol) at recombinant human β~1~-and β~2~-receptors ([@b46-opth-1-93]).

In an animal in vivo model, levobetaxolol was more potent than dextrobetaxolol in reducing IOP by a maximum of 25.9 ± 3.2%, whereas the same dose of dextrobetaxolol reduced IOP by 15.5 ± 3.6%; the efficacy of racemic betaxolol was very similar to that of levobetaxolol ([@b46-opth-1-93]).

Topical treatment with betaxolol has been shown to reduce IOP significantly in normal subjects, and in POAG and OHT patients in placebo-controlled studies ([@b38-opth-1-93];[@b6-opth-1-93];[@b13-opth-1-93]), as well as in masked comparisons with timolol ([@b5-opth-1-93];[@b2-opth-1-93];[@b48-opth-1-93]), and levobunolol ([@b25-opth-1-93]). All these drugs have been found comparable with regard to their efficacy in lowering IOP; however, the decrease of IOP has been found to be significantly smaller with betaxolol compared with timolol or levobunolol in a number of clinical trials ([@b38-opth-1-93];[@b6-opth-1-93];[@b5-opth-1-93];[@b13-opth-1-93];[@b48-opth-1-93];[@b2-opth-1-93];[@b25-opth-1-93];[@b28-opth-1-93];[@b21-opth-1-93];[@b59-opth-1-93]).

In two controlled clinical studies, in which a total of 356 patients were dosed for 3 months, betaxolol ophthalmic suspension produced clinically relevant reductions in IOP at all follow-up visits. At 8 AM after night-time dosing (trough), IOP was reduced from baseline by approximately 4--5 mmHg (16%--21%). At 10 AM, 2 hours after dosing (peak), IOP was reduced from baseline by approximately 5--6 mmHg (20% to 23%) ([@b54-opth-1-93]).

Adverse effects
===============

Although betaxolol is pharmacodynamically selective for β~1~-adrenoreceptors, the extent of β~1~-receptor occupancy of topically applied betaxolol in the systemic circulation has been found to be less than that of the three non-selective blockers: timolol, levobunolol, and carteolol ([@b36-opth-1-93];[@b58-opth-1-93]); this indicates a lesser systemic β~1~-blocking activity of betaxolol, associated with negligible systemic β~2~-blockade, which provides a better safety profile for the drug.

Systemic absorption allows topical β-adrenergic blockers to cause adverse effects on pulmonary, cardiac and central nervous system ([@b51-opth-1-93];[@b24-opth-1-93]). Non-selective β-blockers commonly used in glaucoma therapy cause bronchopulmonary constriction and depress cardiovascular performance ([@b24-opth-1-93];[@b46-opth-1-93]) while selective β-blockers such as betaxolol and levobetaxolol do not have this side effect. In the heart β~1~-adrenoceptors predominate, while in the lung and trachea there is a predominance of β~2~-adrenoceptors ([@b41-opth-1-93];[@b19-opth-1-93];[@b42-opth-1-93]).

[@b45-opth-1-93] determined the relative affinities and selectivities of timolol, levobunolol, levobetaxolol racemic betaxolol, and other β-blockers at the native β~1~- and β~2~-adrenoceptors in guinea pig heart and lung using radioligand binding, demonstrating that racemic betaxolol and levobetaxolol exhibited a higher affinity and greater selectivity for the β-adrenoceptors than the destro enantiomer.

Betaxolol and levobetaxolol possessed a 193- to 233-fold selectivity for β~1~-receptors, and levobunolol a 140-fold selectivity for β~2~-receptors; timolol was essentially non-selective.

Any ocular hypotensive treatment that can reduce blood pressure and heart rate can act as an additional risk factor in the development and progression of POAG ([@b37-opth-1-93]). Most of the studies have shown the lack of effects of betaxolol on the cardiovascular system ([@b4-opth-1-93];[@b6-opth-1-93];[@b13-opth-1-93];[@b5-opth-1-93];[@b25-opth-1-93]).

Due to the very low binding affinity to pulmonary β~2~-receptors, betaxolol is generally well tolerated and does not produce significant modification of pulmonary function tests in glaucoma patients with asthma and chronic obstructive pulmonary disease ([@b56-opth-1-93];[@b52-opth-1-93];[@b15-opth-1-93];[@b43-opth-1-93]).

However, it should be remembered that some pulmonary complications have also been reported associated with betaxolol treatment ([@b17-opth-1-93];[@b40-opth-1-93]).

Effects on ocular blood flow
============================

Betaxolol can improve ocular perfusion, increasing blood velocity in retinal and epipapillary capillaries ([@b3-opth-1-93]); can increase end-diastolic velocity and decrease resistance index trough (determined by color Doppler imaging), a vasorelaxant effect in retrobulbar vessels (posterior ciliary arteries, central retinal artery) ([@b18-opth-1-93];[@b47-opth-1-93]); and can increase retinal blood flow as a long-term effect after drug application ([@b60-opth-1-93]).

[@b23-opth-1-93] demonstrated the vasorelaxant effects of DL-betaxolol, D-betaxolol, and L-betaxolol on bovine retinal vessels. The compounds had the same vasodilatatory effect without statistically significant differences.

Levobetaxolol would have the same action on blood ocular vessels as racemic betaxolol (unrelated to stereoselective β-blocking activity), perhaps involving an interaction with calcium channels.

Calcium-sodium channel blocking activity and neuroprotection
============================================================

β~1~-blockers can act as neuroprotectants by reducing sodium influx into cells acting as; they can also protect insulted neurones by reducing calcium influx. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium influx ([@b27-opth-1-93];[@b8-opth-1-93];[@b35-opth-1-93]).

An ischemic-like insult to the optic nerve causes a decline of ATP and failure of the NA^+^/K^+^-ATPase, which leads to an accumulation of intra-axonal sodium. This rise in intracellular sodium leads to reversal of the NA^+^/Ca^2+^ exchanger, which imports damaging quantities of calcium into the intracellular compartment. Elevated extracellular concentrations of glutamate cause excitotoxic injury, leading to an excessive stimulation of ganglion cell glutamate receptors and an entry of Ca^+^ and Na^+^ ions. This rise in ion concentration will activate the opening of voltage-gated channels and cause a greater elevation of Na^+^ and Ca^+^ concentration, a trigger for a cascade of events that lead to cell death.

Glutamate receptor antagonist or the use of sodium or calcium channel blockers can protect the ganglion cell bodies from excitotoxic injury. Glutamate antagonists would not be effective at the axonal level, so to protect the entire ganglion cell in glaucoma, the ideal way would be that of using a glutamate receptor antagonist together with a sodium-channel blocker or a substance that prevents the reversal of sodium/calcium exchanger ([@b35-opth-1-93]).

Betaxolol can inhibit Na^+^ influx modulating the gating mechanism of the Na^+^ channel, not interfering with ion conductance directly. Betaxolol inhibited veratridine-stimulated (lipophilic toxin that causes a persistent activation of the Na^+^ channel) Na^+^ influx into rat cortical synaptosomes without statistically significant differences between the effects of levobetaxolol and that of racemic betaxolol, so that it is possible to conclude that stereoselectivity is not relevant to the affinity of betaxolol for the neurotoxin site 2 of the Na^+^ channel. Atenolol, timolol, levobunolol, and cateolol were significantly less active than betaxolol ([@b8-opth-1-93]).

It has been demonstrated that betaxolol has an affinity for the L-type voltage-gated calcium channel and is able to counteract the N-methyl-D-aspartate-induced influx of radioactive calcium into the retina ([@b26-opth-1-93]).

[@b35-opth-1-93], using an ischemia/reperfusion model recording flash electroretinograms after a reperfusion period in ischemic rat retinas, showed that levobetaxolol is more effective than timolol as a neuroprotectant.

Levobetaxolol demonstrates a higher affinity than dextrobetaxolol against L-type Ca^+^ channels, but no significant affinity at N-type Ca^+^ channels. Levobetaxolol is able to counteract the NMDA-induced influx of radioactive calcium into rat retinas ([@b46-opth-1-93];[@b26-opth-1-93]). This L-type Ca^+^ channel blocking activity is clinically relevant because an increase in optic nerve head blood flow and beneficial effects on visual fields in glaucoma patients are associated with various Ca^2+^-antagonists ([@b7-opth-1-93];[@b22-opth-1-93]).

Levobetaxolol could act as a neuroprotectant both for the axon (in which voltage-sensitive sodium channels are responsible for generation and propagation of action potentials) ([@b8-opth-1-93]), and for the cell body and dendrites, reducing the toxic influx of calcium glutamate-mediated ([@b35-opth-1-93]) blocking of both calcium and sodium channels.

Furthermore, it has been shown that systemic dosed levobetaxolol exerts a neuroprotective action in photic-induced retinal damage. This molecule can upregulate endogenous b-fibroblast growth factor and ciliary neurotrophic factor-mRNA (two growth factors implicated in the protection of photoreceptor cells). Levobetaxolol was able to protect the retinal function (tested with an electroretinogram), and to prevent changes in retinal morphology after photic-induced retinopathy ([@b1-opth-1-93]).

Conclusions
===========

Betaxolol is a well-documented drug in glaucoma therapy, and its efficacy in lowering the IOP is comparable with that of the non-selective β-blockers.

Betaxolol offers a superior safety profile, especially in patients with cardio-pulmonary diseases. Due to the calcium channel-blocker activity, betaxolol has all the characteristics for improving ocular perfusion and protecting retinal ganglion cells from loss related to glaucoma.
